Stock Price Quote

ALKEM LABORATORIES LTD.

NSE : ALKEMBSE : 539523ISIN CODE : INE540L01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE5037.25-23.05 (-0.46 %)
PREV CLOSE ( ) 5060.30
OPEN PRICE ( ) 5029.80
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 8100
TODAY'S LOW / HIGH ( )4946.10 5094.60
52 WK LOW / HIGH ( )2835.05 5519.1
NSE5044.05-17.8 (-0.35 %)
PREV CLOSE( ) 5061.85
OPEN PRICE ( ) 5010.00
BID PRICE (QTY) 5044.05 (138)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 678534
TODAY'S LOW / HIGH( ) 4934.65 5096.35
52 WK LOW / HIGH ( )3042.3 5520
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 08-08 1973
Management Info
Basudeo N Singh - Chairman Sandeep Singh - Managing Director
Registered Office

Address Alkem House,Senapati Bapat Marg,Lower Parel (West),
Mumbai,
Maharashtra-400013

Phone 022 3982 9999

Email investors@alkem.com / contact@alkem.com

Website www.alkemlabs.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

27Feb Alkem Laboratories informs about clari
Alkem Laboratories has informed that the Company is in compliance with t..
26Feb Alkem Laboratories informs about clari
Alkem Laboratories has informed that it enclosed the clarification lette..
16Feb Alkem Laboratories informs about discl
Alkem Laboratories has informed that the exchange has received the discl..
14Feb Alkem Laboratories informs about trans
Alkem Laboratories has informed that it enclosed the transcript of the ‘..
12Jan Announcement under Regulation 30 (LOD
We wish to inform you that the Company has appointed Mr. Nitin Agrawal a..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit5042.311344.7
Gross Profit 5343.8 13269.9
Operating Profit 6649.216432.4
Net Sales 24945.990545.5

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  28639.35 (0.55%)
M.Cap ( in Cr)60856.62
Bharat Parenterals (BSE)
peergroup  1147.65 (10.28%)
M.Cap ( in Cr)667.89
Astrazeneca Pharma I (BSE)
peergroup  5567.65 (1.95%)
M.Cap ( in Cr)13919.13
Neuland Laboratories (BSE)
peergroup  7063.75 (1.37%)
M.Cap ( in Cr)9062.71
Mankind Pharma (BSE)
peergroup  2097.55 (1.58%)
M.Cap ( in Cr)84025.43

Shareholding Pattern

PROMOTERS 56.74%
FI/BANKS/INSURANCE 2.86%
NON-INSTITUTION 18.86%
MUTUAL FUNDS/UTI 12.08%
GOVERNMENT 0%
FII 0%

About Alkem Laboratories Ltd.

Alkem Laboratories Ltd. was incorporated in the year 1973. Its today's share price is 5037.25. Its current market capitalisation stands at Rs 60227.88 Cr. In the latest quarter, company has reported Gross Sales of Rs. 95173.6 Cr and Total Income of Rs.93208.4 Cr. The company's management includes Sujjain Talwar, Dheeraj Sharma, Sudha Ravi, Sangeeta Singh, Narendra Kumar Aneja, Arun Kumar Purwar, Srinivas Singh, Sarvesh Singh, Madhurima Singh, Mritunjay Kumar Singh, Sandeep Singh, Basudeo N Singh, Manish Narang.

It is listed on the BSE with a BSE Code of 539523 , NSE with an NSE Symbol of ALKEM and ISIN of INE540L01014. It's Registered office is at Alkem House,Senapati Bapat Marg,Lower Parel (West)Mumbai-400013, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, RS Sanghai & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.